[1]
Luchsinger JA. Diabetes, related conditions, and dementia. J Neurol Sci 2010; 299(1): 35-8.
[2]
Natan MB, Danino S, Freundlich N, Barda A, Yosef RM. Intention of nursing students to work in geriatrics. Res Gerontol Nurs 2015; 8(3): 140-7.
[3]
Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. The Honolulu-Asia Aging Study Diabetes 2002; 51(4): 1256-62.
[4]
Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, et al. Diabetes mellitus and risk of developing Alzheimer disease: Results from the framingham study. Arch Neurol 2006; 63(11): 1551-5.
[5]
Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA. Type 2 diabetes and late-onset alzheimer’s disease. Dement Geriatr Cogn Disord 2011; 31(6): 424-30.
[6]
Patrone C, Eriksson O, Lindholm D. Diabetes drugs and neurological disorders: New views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014; 2(3): 256-62.
[7]
Markowicz-Piasecka M, Sikora J, Szydłowska A, Skupień A, Mikiciuk-Olasik E, Huttunen KM. Metformin- A future therapy for neurodegenerative diseases. Pharm Res 2017; 34(12): 2614-27.
[8]
Ascher-Svanum H, Chen YF, Hake A, Kahle-Wrobleski K, Schuster D, Kendall D, et al. Cognitive and functional decline in patients with mild alzheimer dementia with or without comorbid diabetes. Clin Therapeut 2015; 37(6): 1195-205.
[9]
Banks WA, Owen JB, Erickson MA. Insulin in the brain: There and back again. Pharmacol Ther 2012; 136(1): 82-93.
[10]
Li J, Cesari M, Liu F, Dong B, Vellas B. Effects of diabetes mellitus on cognitive decline in patients with Alzheimer disease: A systematic review. Can J Diabetes 2017; 41(1): 114-9.
[11]
Strachan MW, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship between type 2 diabetes and dementia. Br Med Bull 2008; 88(1): 131-46.
[12]
González-Reyes ER, Aliev G, Ávila-Rodrigues M, Barreto EG. Alterations in glucose metabolism on cognition: A possible link between diabetes and dementia. Curr Pharm Des 2016; 22(7): 812-8.
[13]
Bowling A. Research methods in health: Investigating health and health services. 4th ed. Milton Keynes: Open University Press 2014.
[14]
Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011; 24(3): 485-93.
[15]
Bruce DG, Davis WA, Casey GP, Starkstein SE, Clarnette RM, Foster J, et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia 2008; 51(2): 241-8.
[16]
Herath PM, Cherbuin N, Eramudugolla R, Anstey KJ. The effect of diabetes medication on cognitive function: evidence from the PATH Through Life study. BioMed Res Int 2016; 20167208429
[17]
Asadbegi M, Yaghmaei P, Salehi I, Ebrahim-Habibi A, Komaki A. Neuroprotective effects of metformin against Aβ-mediated inhibition of long-term potentiation in rats fed a high-fat diet. Brain Res Bull 2016; 121: 178-85.
[18]
Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology 2011; 60(6): 910-20.
[19]
Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: A population-based case-control study. J Am Geriatr Soc 2012; 60(5): 916-21.
[20]
Momtaz YA, Hamid TA, Haron SA, Bagat MF. Flourishing in later life. Arch Gerontol Geriatr 2016; 63: 85-91.
[21]
Shahar S, Omar A, Vanoh D, Hamid TA, Mukari SZMS, Din NC, et al. Approaches in methodology for population-based longitudinal study on neuroprotective model for healthy longevity (TUA) among Malaysian Older Adults. Aging Clin Exp Res 2016; 28(6): 1089-104.
[22]
Ibrahim NM, Shohaimi S, Chong HT, Rahman AH, Razali R, Esther E, et al. Validation study of the mini-mental state examination in a Malay-speaking elderly population in Malaysia. Dement Geriatr Cogn Disord 2009; 27(3): 247-53.
[23]
Yuan X, Liu T, Wu L, Zou ZY, Li C. Validity of self-reported diabetes among middle-aged and older Chinese adults: The China health and retirement longitudinal study. BMJ Open 2015; 5(4)e006633
[24]
Keel S, Foreman J, Xie J, van Wijngaarden P, Taylor HR, Dirani M. The prevalence of self-reported diabetes in the Australian national eye health survey. PLoS One 2017; 12(1)e0169211
[25]
Xaverius PK, Salas J, Kiel D. Differences in pregnancy planning between women aged 18-44, with and without diabetes: Behavioral risk factor surveillance system analysis. Diabetes Res Clin Pract 2013; 99(1): 63-8.
[26]
Hamid TA, Krishnaswamy S, Abdullah SS, Momtaz YA. Sociodemographic risk factors and correlates of dementia in older Malaysians. Dement Geriatr Cogn Disord 2010; 30(6): 533-9.
[27]
Momtaz YA, Hamid TA, Yusoff S, Ibrahim R. Do depression and educational attainment mediate the association between ethnicity and dementia? Gerontology 2013; 59(3): 206-12.
[28]
Kim HY. Statistical notes for clinical researchers: Assessing normal distribution (2) using skewness and kurtosis. Restor Dent Endod 2013; 38(1): 52-4.
[29]
Francisco PM, Belon AP, Barros MB, Carandina L, Alves MC, Goldbaum M, et al. Self-reported diabetes in the elderly: Prevalence, associated factors, and control practices. Public Health Notebooks 2010; 26(1): 175-84.
[30]
Rampal S, Rampal L, Rahmat R, Zain AM, Yap YG, Mohamed M, et al. Variation in the prevalence, awareness, and control of diabetes in a multiethnic population: A nationwide population study in Malaysia. Asia Pac J Public Health 2010; 22(2): 194-202.
[31]
Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes- Systematic overview of prospective observational studies. Diabetologia 2005; 48(12): 2460-9.
[32]
Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999; 16(2): 93-112.
[33]
Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: A meta‐analysis of longitudinal studies. Intern Med J 2012; 42(5): 484-91.
[34]
Hasan SS. A comparative drug utilisation study of the treatment of diabetes in Malaysia and Australia. Australas Med J 2015; 8(6): 179-88.
[35]
Campbell JM, Stephenson MD. Courten Bd, Chapman I, Bellman SM, Aromataris E. Metformin use associated with reduced risk of dementia in patients with diabetes: A systematic review and meta-analysis. J Alzheimers Dis 2018; 65(4): 1225-36.
[36]
Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 2014; 41(1): 61-8.
[37]
Podhorecka M, Ibanez B, Dmoszyńska A. Metformin- Its potential anti-cancer and anti-aging effects. Postepy Hig Med Dosw 2017; 71: 170-5.
[38]
Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 2009; 106(10): 3907-12.
[39]
Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E. Metformin and Alzheimer’s disease, dementia and cognitive impairment: A systematic review protocol. JBI Database System Rev Implement Rep 2017; 15(8): 2055-9.
[40]
Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004; 57(10): 1096-103.
Download PDF Flyer